Loading...

For more information on the Genta clinical development program, please contact us at ClinicalTrials@genta.com or at http://www.clinicaltrials.gov

Information for Patients

Loading...

Melanoma

Malignant melanoma is the most deadly form of skin cancer. The annual incidence of melanoma is increasing by about 4%, an incidence that represents the most rapid increase of any cancer type.1

  • Melanoma is the most common cancer in young adults ages 20 to 30.1
  • Melanoma is the leading cause of cancer death in women ages 25 to 30.1
  • Annual worldwide incidence of malignant melanoma is 132,000 with 66,000 people dying annually of melanoma and other skin cancers.2
  • Melanoma kills an estimated 94% of stage IV patients within 5 years of the diagnosis of metastases.3

More information about melanoma can be found at the following advocacy organizations web sites:

Loading...

 

mrf
  Melanoma Research Foundation
 aim-at-melanoma  Aim at Melanoma Foundation:
 Aim for Answers. Aim for Action. Aim for a Cure.
 americancancersociety  American Cancer Society 
 

References

  1. Melanoma Research Foundation Fact Sheet
  2. World Health Organization
  3. Prognostic Factors in 1,521 Melanoma Patients with Distant Metastases, J Am Coll Surg, 1995; 181(3):263-265
Loading...
Loading...
Loading...
Mechanism of Action
Bcl-2 protein is a key inhibitor of apoptotic cell death.

Read More

Loading...
Preclinical Data

Genasense (oblimersen sodium) Injection has been studied with most types of anticancer therapies.

Read More

Loading...
Technology
Genasense reduces the expression of Bcl-2 protein by a technology known as “antisense”.

Read More

Loading...